IDO1/TDO-IN-4 (compound 28, i.p., 20 mg/kg, at day 1, 2, 3) rescues LPS-induced neuroinflammation and depressive-like behavior in mice[1].
IDO1/TDO-IN-4 (I.p. or i.v., 20 mg/kg) displays high exposure and a high volume of distribution at the steady state in normal mice[1].
| Animal Model: | 2 mg/kg LPS-induced depressive mice[1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), at day 1, 2, 3. |
| Result: | Attenuated microglial activation significantly.
Decreased inflammatory factors in the hippocampus, such as TNF-α, IL-1β, and iNOS.
Downregulated LPS-induced overexpression of IDO1.
|
| Animal Model: | Male C57BL/6J mice (pharmacokinetic assay)[1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection and intravenous injection |
| Result: | Pharmacokinetic profile of IDO1/TDO-IN-4 (compound 28)
| pharmacokinetic property | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | bioavailability F (%) | | i.v./i.p. | 2.31/0.77 | 0.25 | 5543.99/3878 | 52.55 |
|
![9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Structure](/CAS/20210305/GIF/461424-21-5.gif)
